Long-term effects of interferon therapy on histology and development of hepatocellular carcinoma in hepatitis C

Journal of Gastroenterology and Hepatology (Australia)

Volumn 15, Issue SUPPL. MAY, 2000, Pages

  Omata, Masao ^a   Shiratori, Yasushi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALCOHOL; INTERFERON; VIRUS RNA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALCOHOL CONSUMPTION; CLINICAL TRIAL; CONFERENCE PAPER; DISEASE COURSE; DRUG EFFICACY; FOLLOW UP; HEPATITIS C; HUMAN; IMMUNOTHERAPY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER HISTOLOGY; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; REMISSION; RISK FACTOR; TREATMENT OUTCOME;

EID: 0033947569     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1746.2000.02115.x     Document Type: Conference Paper

References (48)

1. Di Bisceglie AM, Goodman ZD, Ishak KG, Hoofnagle JH, Melpolder JJ, Alter HJ. Long-term clinical and histopathological follow-up of chronic post transfusion hepatitis. Hepatology 1991; 14: 969-74.
2. Seef LB, Buskell-Bales Z, Wright EG et al Long-term mortality after transfusion-associated non-A, non-B hepatitis. N. Engl. J. Med. 1992; 327: 1906-11.
3. Tong MJ, Neveen S, El-Farra NS, Reikes AR, Co RL. Clinical outcomes after transfusion-associated hepatitis C. N. Engl. J. Med. 1995; 332: 1463-6.
4. Fattovich G, Giusta G, Degos F et al. Morbidity and mortality in compensated cirrhosis type C: A retrospective follow-up study of 384 patients. Gastroenterology 1997; 112: 463-72.
5. De Bisceglie AM, Goodman ZD, Ishak KG, Hoofnagle JY, Melpolder JJ, Alter HJ. Long-term clinical and histopathological follow-up of chronic posttransfusion hepatitis. Hepatology 1991; 14: 969-74.
6. Yano M, Kumada H, Kage M et al. The long-term pathological evolution of chronic hepatitis C. Hepatology 1996; 23: 1334-40.
7. Kage M, Shimamatsu K, Nakashima F, Kojiro M, Inoue O, Yano M. Long-term evolution of fibrosis from chronic hepatitis to cirrhosis in patients with hepatitis C: morphometric analysis of repeated biopsies. Hepatology 1997; 25: 1028-31.
8. Hoofnagle JH, Di Bisceglie AM. The treatment of chronic viral hepatitis. N. Engl. J. Med. 1997; 336: 347-56.
9. Lau JYM, Davis GL, Kniffen J et al. Significance of serum hepatitis C virus RNA levels in chronic hepatitis C. Lancet 1993; 341: 1501-4.
10. Shiratori Y, Kato N, Yokosuka O et al. Predictors of the efficacy of interferon therapy in chronic hepatitis C virus infection. Gastroenterology 1997; 113: 558-66.
11. Poynard T, Leroy V, Cohard M et al. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology 1996; 24: 778-89.
12. Lindsay KL. Therapy of hepatitis C: overview. Hepatology 1997; 26 (Suppl 1); S71-7.
13. Chemello L, Cavalletto L, Casarin C et al. Persistent hepatitis C viremia predicts late relapse after sustained response to interferon-alpha in chronic hepatitis C. Ann. Intern. Med. 1996; 124: 1058-60.
14. Reichard O, Glaumann H, Fryden A et al. Two-year biochemical, virological, and histological follow-up in patients with chronic hepatitis C responding in a sustained fashion to interferon alfa-2b treatment. Hepatology 1995; 21: 918-22.
15. Manesis EK, Papaioannou C, Gioustozi A, Kafiri G, Koskinas J, Hadziyannis SJ. Biochemical and virological outcome of patients with chronic hepatitis C treated with interferon alfa-2b for 6 or 12 months: A 4-year follow-up of 211 patients. Hepatology 1997; 26: 734-9.
16. Shiffmann M, Hoofmann CM, Thompson EB et al. Relationship between biochemical, virological, and histological response during interferon treatment of chronic hepatitis C. Hepatology 1997; 26: 780-5.
17. Scheuer PJ. Classification of chronic viral hepatitis: a needed reassessment. J. Hepatol. 1991; 13: 372-4.
18. Knodell RG, Ishak KG, Black WC et al. Formulation and application of a numerical scoring system for assessing histologic activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1: 431-5.
19. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: Diagnosis, grading and staging. Hepatology 1994; 19: 1513-20.
20. Bedossa P, Poynard T, for the METAVIR group. An algorithm for the grading of activity in chronic hepatitis C. Hepatology 1996; 24: 289-93.
21. The French METAVIR cooperative study group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology 1994; 20: 15-20.
22. Poynard T, Bedossa P, Oplon P, for the OBSTIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 1997; 349: 825-32.
23. Mathurin P, Moussalli J, Cadranel JF et al. Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity. Hepatology 1998; 27: 868-72.
24. Shiratori Y, Imazeki F, Moriyama M et al. Histological improvement of fibrosis in hepatitis C patients with sustained response to interferon therapy: long-term follow-up study using paired biopsy samples. Gastroenterology 1999; AGA abstract.
25. Camma C, Giunta M, Linea C, Pagliaro L. The effect of interferon on the liver in chronic hepatitis C: a quantitative evaluation of histology by meta-analysis. J. Hepatol. 1997; 26: 1187-99.
26. Bonis PA, Ioannidis JPA, Cappelleri JC, Kaplan MM, Lau J. Correlation of biochemical response to interferon alfa with histological improvement in hepatitis C: A metaanalysis of diagnostic test characteristics. Hepatology 1997; 26: 1035-44.
27. Ziol M, Van Nhieu JT, Roudot-Thoraval F et al. A histopathological study of the effects of 6-month versus 12-month interferon alfa-2b therapy in chronic hepatitis C. J. Hepatol. 1996; 25: 833-41.
28. Tsubota A, Kumada H, Chayama K et al. Time course of histological changes in patients with a sustained biochemical and virological response to interferon-alfa therapy for chronic hepatitis C virus infection. J. Hepatol. 1997; 27: 49-55.
29. Reichard O, Glaumann H, Weiland O. Long-term histological outcome in patients with chronic hepatitis C treated repeatedly with interferon alpha-2b without sustained response. Scand. J. Infect. Dis. 1994; 26: 383-9.
30. Sobesky R, Mathurin P, Charlotte F et al. Modeling the impact of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C: A dynamic view. Gastroenterology 1999; 116: 378-86.
31. Lau DTY, Kleiner DE, Ghany MG, Park Y, Schmid P, Hoofnagle JH. 10-year follow-up after interferon-alfa therapy for chronic hepatitis C. Hepatology 1998; 28: 1121-7.
32. Marcellin P, Boyer N, Gervais A et al. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alfa therapy. Ann. Intern. Med. 1997; 127: 875-81.
33. Colombo M, de Franchis R, del Ninno E, Sangivanni A, De Fazio C, Tommasini M. Hepatocellular carcinoma in Italian patients with cirrhosis. N. Engl. J. Med. 1991; 325: 675-80.
34. Tsukuma H, Hiyama T, Tanaka S et al. Risk factor for hepatocellular carcinoma among patients with chronic liver disease. N. Engl. J. Med. 1993; 328: 1797-1801.
35. Takano S, Yokosuka O, Imazeki F, Tagawa M, Omata M. Incidence of hepatocellular carcinoma in chronic hepatitis B and C: a prospective study of 251 patients. Hepatology 1995; 21: 650-5.
36. Nishiguchi S, Kuroki T, Nakatani S et al. Randomized trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis with cirrhosis. Lancet 1995; 346: 1051-5.
37. Mazella G, Accogli E, Sottili S et al. Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis. J. Hepatol. 1996; 24: 141-7.
38. Fattovich G, Giustina G, Degos F et al. Effectiveness of interferon alfa on incidence of hepatocellular carcinoma and decompensation in cirrhosis type C. J. Hepatol. 1997; 27: 201-5.
39. Niederau C, Lange S, Heintges T et al. Prognosis of chronic hepatitis C: results of a large prospective cohort study. Hepatology 1998; 28: 1687-95.
40. Serfaty L, Aumatre H, Chazouileres O et al. Determinants of outcome of compensated hepatitis C virus-related cirrhosis. Hepatology 1998; 27: 1435-40.
41. Kuwana K, Ichida T, Kamimura T et al. Risk factors and the effect of interferon therapy in the development of hepatocellular carcinoma: a multivariate analysis in 343 patients. J. Gastroenterol. Hepatol. 1997; 12: 149-55.
42. International Interferon-alfa Hepatocellular Carcinoma Study Group. Effect of interferon-alfa on progression of cirrhosis to hepatocellular carcinoma: a retrospective cohort study. Lancet 1998; 351: 1535-9.
43. Kasahara A, Hayashi N, Kochizuki K et al. Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Hepatology 1998; 27: 1394-1402.
44. Imai Y, Kawata S, Tamura S et al. Relation of interferon therapy and hepatocellular carcinoma patients with chronic hepatitis C. Ann. Intern. Med. 1998; 129: 94-9.
45. Ikeda K, Saitoh S, Arase Y et al. Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: a long-term observation study of 1643 patients using statistical bias correction with proportional hazard analysis. Hepatology 1999; 29: 1124-30.
46. Okanoue T, Itoh Y, Minami M et al. Interferon therapy lowers the rate of progression to hepatocellular carcinoma in chronic hepatitis C, but not significantly in an advanced stage: a retrospective study in 1148 patients. J. Hepatol. 1999; 30: 653-9.
47. Shindo M, Ken A, Ikuno T. Varying incidence of cirrhosis and hepatocellular carcinoma in patients with chronic hepatitis C responding differently to interferon therapy. Cancer 1999; 85: 1943-50.
48. Yoshida H, Shiratori Y, Moriyama M et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program in Japan of cirrhotic and non-cirrhotic patients with chronic hepatitis C. Ann. Intern. Med. 1999; 131: 174-81.